“We are committed to improving and saving the lives of babies and young children with congenital hyperinsulinism, a rare and life-threatening disease. Like all biotech and pharmaceutical companies in San Diego and around the world, we follow the international guidelines for assessing safety of drug candidates published by the International Council for Harmonisation (ICH), which are required by the U.S. FDA and other international regulatory bodies for every drug candidate being studied. We follow strict guidelines in these studies to ensure the proper care and welfare of the animals and require our contractors to do the same. In reference to one of our contractors, Inotiv, we were appalled by the recent findings of the Department of Justice regarding their Virginia facility. Although the studies we are conducting with Inotiv are not associated with this particular facility, the DOJ complaint highlighted activities that run directly counter to our core values and the expectations we require of all of our contractors. We will continue to work closely with the FDA and other international regulatory bodies and welcome the opportunity to partner with them to work toward a future generation of safe, rigorous testing methods.”

- Attribute to: Scott Struthers, Ph.D., Founder and Chief Executive Officer, Crinetics Pharmaceuticals